gp130/CD130 Antibody (28126) [Unconjugated]

Recombinant Human Oncostatin M/OSM stimulates proliferation in the TF‑1 human erythroleukemic cell line (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human Oncostatin M/OSM (0.8 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human gp130 Monoclonal Antibody (Catalog # MAB228). The ND50 is typically 0.04-0.2 µg/mL.

• Reactivity: Hu
• Applications: Flow, B/N, CyTOF-ready
• Clone: 28126
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

gp130/CD130 Antibody (28126) [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human gp130 extracellular domain
• Specificity: Detects human gp130 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) IL-2 R, rhIL-4 R, or rhIL-6 R is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL6ST
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells
  • Neutralization 0.04-0.2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for gp130/CD130 Antibody (28126) [Unconjugated]

• CD130 antigen
• CD130
• CDw130
• DKFZp564F053
• gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form
• gp130
• IL-6 receptor subunit beta
• IL-6R subunit beta
• IL-6RB
• IL-6R-beta
• IL6ST
• interleukin 6 signal transducer (gp130, oncostatin M receptor)
• interleukin receptor beta chain
• interleukin-6 receptor subunit beta
• Interleukin-6 signal transducer
• Membrane glycoprotein 130
• membrane glycoprotein gp130
• Oncostatin-M receptor subunit alpha

Background

Glycoprotein 130 (gp130; also known as IL-6 signal transducer, IL-6 receptor beta, oncostatin-M alpha subunit) is a ubiquitously expressed, 130 kDa type I transmembrane glycoprotein and member of the type II subfamily, type I cytokine receptor family. Functionally, it is responsible for transduction of the IL-6 signal across the plasma membrane (1). Rat gp130 is synthesized as a 918 amino acid (aa) precursor with a 22 aa signal sequence, a 596 aa extracellular domain (ECD), a 22 aa transmembrane region, and a 278 aa cytoplasmic tail. Eleven potential N-linked glycosylation sites are found within the rat gp130 ECD (1). The ECD also contains an N terminal immunoglobulin (Ig)-like C2-type domain, followed by the cytokine receptor homology region (CHR) which is made up of two fibronectin type III-like domains and a WSXWS motif, and three additional fibronectin type III-like domains (2). The domains in the CHR are the structural hallmarks of the hematopoietic cytokine receptor family (2). Human gp130 shares 73% and 79% aa sequence identity with mouse and rat gp130, respectively. Gp130 serves as the signal transducing receptor subunit for the IL-6-type cytokines consisting of interleukin (IL)-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), new neurotrophin factor-1 (NNT-1), IL-27, cardiotrophin-1 (CT-1), and cardiotrophin like cytokine (CLC) (2 - 5). These cytokines are involved in a variety of functions including the modulation of inflammatory and immune responses, heart development, fertility, and many other activities (2).

1. Wang, Y. et al. (1992) Genomics 14:666.
2. Muller-Newen, G. (2003) Sci. STKE pe40.
3.  Heinrich, P.C. et al. (2003) Biochem. J. 374:1.
4. Stuhlmann-Laeisz, C. et al. (2006) Mol. Biol. Cell 17:2986.
5. Fischer, P. and D. Hilfiker-Kleiner (2008) Br. J. Pharmacol. 153:S414.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for gp130/CD130 Antibody (MAB228)(10)

Publications using MAB228

• Katarzyna Składanowska, Yehudi Bloch, Jamie Strand, Kerry F. White, Jing Hua, Daniel Aldridge et al. Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27 Cell Reports 10/18/2022 [PMID: 36261006]
• Jie Cheng, Timothy G. Myers, Callie Levinger, Princy Kumar, Jai Kumar, Bruktawit A. Goshu et al. IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells iScience 1/21/2022 [PMID: 35005538]
• Ethan L. Morgan, Andrew Macdonald Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1—NF kappa B—IL-6 signalling axis PLOS Pathogens 6/21/2019 [PMID: 31226168]
• AN Wilkinson, KH Gartlan, G Kelly, LD Samson, SD Olver, J Avery, N Zomerdijk, SK Tey, JS Lee, S Vuckovic, GR Hill Granulocytes Are Unresponsive to IL-6 Due to an Absence of gp130 J. Immunol., 2018-04-06;0(0):. 2018-04-06 [PMID: 29626088] (Flow Cytometry, Human)
• YOUDI HE, NING MA, CHEN XING, XIAOQIAN WANG, HE XIAO, MINGKE ZHENG et al. Novel IL-6-secreting gamma δT cells increased in patients with atherosclerotic cerebral infarction Molecular Medicine Reports 2/1/2015 [PMID: 25351283]
• Sven Kruspe, Cindy Meyer, Ulrich Hahn Chlorin e6 Conjugated Interleukin-6 Receptor Aptamers Selectively Kill Target Cells Upon Irradiation Molecular Therapy - Nucleic Acids 1/21/2014 [PMID: 24481022]
• Cindy Meyer, Katja Eydeler, Eileen Magbanua, Tijana Zivkovic, Nicolas Piganeau, Inken Lorenzen et al. Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells RNA Biology 1/20/2012 [PMID: 22258147]
• Ambarus C, Krausz S, van Eijk M, Hamann J, Radstake T, Reedquist K, Tak P, Baeten D Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods, 2011-10-29;375(1):196-206. 2011-10-29 [PMID: 22075274] (Flow Cytometry, Human)
• Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res., 2009-01-01;69(1):329-37. 2009-01-01 [PMID: 19118018] (Flow Cytometry, Human)
• Erices A, Conget P, Rojas C, Minguell JJ Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp. Cell Res., 2002-10-15;280(1):24-32. 2002-10-15 [PMID: 12372336] (Flow Cytometry, Neutralization, Human)

Bioinformatics

• Gene Symbol: IL6ST